Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Carla Schaubhut"'
Autor:
Claudia Bagutti, Monica Alt Hug, Philippe Heim, Evelyn Ilg Hampe, Philipp Hübner, Timothy R. Julian, Katrin N. Koch, Kerstin Grosheintz, Melanie Kraus, Carla Schaubhut, Rahel Tarnutzer, Eva Würfel, Simon Fuchs, Sarah Tschudin-Sutter
Publikováno v:
Swiss Medical Weekly, Vol 154, Iss 3 (2024)
AIM OF THE STUDY: The COVID-19 pandemic has drawn attention to the benefit of wastewater-based epidemiology, particularly when case numbers are underreported. Underreporting may be an issue with mpox, where biological reasons and stigma may prevent p
Externí odkaz:
https://doaj.org/article/97e7517a0a9545cda83c2943161838ae
Autor:
Jelissa Katharina Peter, Fanny Wegner, Severin Gsponer, Fabrice Helfenstein, Tim Roloff, Rahel Tarnutzer, Kerstin Grosheintz, Moritz Back, Carla Schaubhut, Sabina Wagner, Helena M. B. Seth-Smith, Patrick Scotton, Maurice Redondo, Christiane Beckmann, Tanja Stadler, Andrea Salzmann, Henriette Kurth, Karoline Leuzinger, Stefano Bassetti, Roland Bingisser, Martin Siegemund, Maja Weisser, Manuel Battegay, Sarah Tschudin Sutter, Aitana Lebrand, Hans H. Hirsch, Simon Fuchs, Adrian Egli
Publikováno v:
Microorganisms, Vol 10, Iss 5, p 857 (2022)
(1) Background: Some COVID-19 vaccine recipients show breakthrough infection. It remains unknown, which factors contribute to risks and severe outcomes. Our aim was to identify risk factors for SCoV2 breakthrough infections in fully vaccinated indivi
Externí odkaz:
https://doaj.org/article/9b13e0fcc1e64f10b1dcf474b4592430
Autor:
François Chappuis, Idris Guessous, Thomas Perneger, Manuel Battegay, Laurent Kaiser, Mikaela Smit, Frederique Jacquerioz, Annalisa Marinosci, Giovanni Jacopo Nicoletti, Silvio Ragozzino, Diego O Andrey, Dan Lebowitz, Benjamin Meyer, Herve Spechbach, Julien Salamun, Moritz Back, Carla Schaubhut, Simon Fuchs, Laurent Decosterd, Niklaus D Labhardt
Publikováno v:
BMJ Open, Vol 10, Iss 11 (2020)
Introduction Lopinavir/ritonavir (LPV/r) has been proposed as repurposed drugs for pre-exposure and postexposure prophylaxis as well as therapy of COVID-19. Coronavirus postexposure prophylaxis (COPEP) trial aims at assessing their efficacy as postex
Externí odkaz:
https://doaj.org/article/8d97a7d7d47d435ab1a87d68fdbcfb5b
Autor:
Jelissa Katharina Peter, Fanny Wegner, Severin Gsponer, Fabrice Helfenstein, Tim Roloff, Rahel Tarnutzer, Kerstin Grosheintz, Moritz Back, Carla Schaubhut, Sabina Wagner, Helena Seth-Smith, Patrick Scotton, Maurice Redondo, Christiane Beckmann, Tanja Stadler, Andrea Salzmann, Henriette Kurth, Karoline Leuzinger, Stefano Bassetti, Roland Binggisser, Martin Siegemund, Maja Weisser, Manuel Battegay, Sarah Tschudin Sutter, Aitana Lebrand, Hans H. Hirsch, Simon Fuchs, Adrian Egli
IntroductionCOVID-19 vaccines significantly reduce SARS-CoV-2 (SCoV2)-related hospitalization and mortality in randomized controlled clinical trials, as well as in real-world effectiveness against different circulating SCoV2-lineages. However, some v
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::400890703ba606891a3d356a87a2bbf9
https://doi.org/10.1101/2021.12.23.21268324
https://doi.org/10.1101/2021.12.23.21268324
